Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Intravascular Large B-Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vindesine
Drug: Prednisone

First Posted Date: 2021-05-24

Last Posted Date: 2021-05-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT04899570

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase 1

Recruiting

Conditions: Osteosarcoma
Neuroblastoma
Desmoplastic Small Round Cell Tumor
Malignant Peripheral Nerve Sheath Tumors
Soft Tissue Sarcoma
Melanoma
Ewing Sarcoma
Adrenocortical Cancer
Rhabdoid Tumor
Pediatric Solid Tumor

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: MESNA
Drug: B7-H3 CAR T cells

First Posted Date: 2021-05-21

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT04897321

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Phase 2

Withdrawn

Conditions: Relapsed Acute Myeloid Leukemia
Myelodysplastic Syndromes
Refractory Acute Myeloid Leukemia

Interventions: Biological: Cytokine-induced memory-like NK cells
Procedure: Donor Leukapheresis
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Interleukin-2

First Posted Date: 2021-05-20

Last Posted Date: 2022-03-11

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04893915

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Phase 1

Recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Biological: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
Drug: Bendamustine
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-05-19

Last Posted Date: 2024-10-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 25

Registration Number: NCT04892277

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Methods of T Cell Depletion Trial (MoTD)

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Non Hodgkin Lymphoma
Hodgkin Lymphoma
Chronic Myelogenous Leukemia
Myelofibrosis
Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Multiple Myeloma

Interventions: Drug: Thymoglobulin
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Sirolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2021-05-17

Last Posted Date: 2023-09-28

Lead Sponsor: University of Birmingham

Target Recruit Count: 400

Registration Number: NCT04888741

Locations: 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom

and more 12 locations

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma, B-Cell

Interventions: Drug: CC-220
Drug: Rituximab
Drug: Cyclophosphamide
Drug: CC-99282
Drug: Doxorubicin
Drug: Vincristine
Drug: Polatuzumab vedotin
Drug: Prednisone

First Posted Date: 2021-05-12

Last Posted Date: 2024-10-26

Lead Sponsor: Celgene

Target Recruit Count: 174

Registration Number: NCT04884035

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺
Local Institution - 501, Adelaide, South Australia, Australia
🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

and more 31 locations

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia, in Relapse
Pediatric ALL
Acute Lymphoblastic Leukemia, Refractory

Interventions: Biological: CD19-CAR(Mem) T-cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Device: CliniMACS
Procedure: Leukapheresis

First Posted Date: 2021-05-11

Last Posted Date: 2024-03-06

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 60

Registration Number: NCT04881240

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Brexucabtagene autoleucel

First Posted Date: 2021-05-10

Last Posted Date: 2024-08-14

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 90

Registration Number: NCT04880434

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 37 locations